Insights & Resources – COD Research

Medical Affairs

CT Quality Assurance

Clinical Services

Biometrics

Transforming Complexity into Success: A Large-Scale Global Phase III Biosimilar Dermatology Trial

Strategic Planning for Patient Recruitment

Pulmonary Disease Introduction: Prevalence, Causes, Prevention & Treatment

EMA
FDA
MHRA

HMA / EMA multistakeholder AI and Data forum: Build trustworthy AI on strong data foundations, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 12 November 2026 to 13 November 2026
Source: EMA Published on 2026-09-10
Human medicines European public assessment report (EPAR): Zoledronic acid Mylan, zoledronic acid, Date of authorisation: 23/08/2012, Revision: 18, Status: Authorised
Source: EMA Published on 2026-09-10
First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 5 October 2026, 15:30 (CEST) to 5 October 2026, 17:30 (CEST)
Source: EMA Published on 2026-09-10
Fifth European Medicines Agency (EMA) - Vaccines Europe bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 26 October 2026, 14:00 (CET) to 26 October 2026, 16:00 (CET)
Source: EMA Published on 2026-09-10
Clinical investigation of medicinal products for treatment of migraine - Scientific guideline
Source: EMA Published on 2026-09-10
Draft guideline on clinical investigation of medicinal products for the treatment of migraine and cluster headache - Revision 2
Source: EMA Published on 2026-09-10

Read More